Birchview Capital’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Birchview Capital’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-15,378	Closed	-$23K	–	50
2017 Q4	$23K	Buy	+15,378	New	+$26.5K	0.01%	42

Other funds holding ANTH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Birchview Capital's ANTH Position: Q1 2018 in Review

Birchview Capital sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q1 2018, closing a stake of 15,378 shares — an estimated $23K sold.

Birchview Capital first reported a position in ANTH in Q4 2017 and held it in 1 quarter. The position peaked at $23K in Q4 2017. 28 funds tracked by Wall St. Rank hold ANTH as of Q1 2018.

Birchview Capital reported no remaining Anthera Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Birchview Capital sold 15,378 Anthera Pharmaceuticals, Inc. shares in Q1 2018, an estimated $23K.
Birchview Capital first reported a position in Anthera Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
Birchview Capital's Anthera Pharmaceuticals, Inc. position peaked at $23K in Q4 2017.
28 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q1 2018.

Based on Birchview Capital's 13F filing for Q1 2018, filed 7 May 2018.